*ST生物：筹划收购湖南慧泽生物医药科技有限公司51%股权

Group 1 - The core point of the article is that *ST Bio is planning to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements after the transaction is completed [2] Group 2 - For the fiscal year 2024, *ST Bio's revenue composition is as follows: 73.32% from the stem cell industry, 26.54% from energy-saving technology services, and 0.14% from other industries [2]